{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:15:25Z","timestamp":1758845725307,"version":"3.44.0"},"reference-count":21,"publisher":"Becaris Publishing Limited","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:p>The first paper of this two-part series critically examined the role of composite endpoints in health technology assessments (HTAs) and outlined strategies for determining whether to employ the composite estimate of treatment effect or disaggregate into the component endpoints of the composite and apply separate treatment effects within a modeling framework. In this second paper, we expand the discussion beyond a pivotal trial and consider the way in which additional evidence from the same indication for different drugs in the same class, or the same drug for different indications, could be employed within HTAs. We offer a continuation of the case study of dapagliflozin for the treatment of heart failure with preserved or mildly reduced ejection fraction, where the evidence base was expanded to consider empagliflozin for the same indication, as well as both dapagliflozin and empagliflozin for heart failure with reduced ejection fraction. We conclude that, where there are multiple drugs in the same class and\/or multiple indications for a class of drugs, HTAs should consider the exchangeability of the information that comes from additional evidence beyond the pivotal registration study. Further, we show how consideration of this additional evidence can support the decision concerning whether to disaggregate the components of a composite endpoint or employ the treatment effect from the composite for each endpoint.<\/jats:p>","DOI":"10.57264\/cer-2025-0012","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T10:41:12Z","timestamp":1757500872000},"source":"Crossref","is-referenced-by-count":0,"title":["Composite endpoints in health technology assessment: Part 2 \u2013 expanding the evidence base with a framework for best modeling practice"],"prefix":"10.57264","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0777-1997","authenticated-orcid":false,"given":"Andrew","family":"Briggs","sequence":"first","affiliation":[{"name":"Department of Health Services Research &amp; Policy, London School of Hygiene &amp; Tropical Medicine, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jieling","family":"Chen","sequence":"additional","affiliation":[{"name":"Global Market Access &amp; Pricing, AstraZeneca R&amp;D, Gaithersburg, MD 20878, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Booth","sequence":"additional","affiliation":[{"name":"Health Economics &amp; Outcomes Research Ltd, Cardiff, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason A","family":"Davis","sequence":"additional","affiliation":[{"name":"Health Economics &amp; Outcomes Research Ltd, Cardiff, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0261-4634","authenticated-orcid":false,"given":"Aris","family":"Angelis","sequence":"additional","affiliation":[{"name":"Department of Health Services Research &amp; Policy, London School of Hygiene &amp; Tropical Medicine, London, UK"},{"name":"General Secretariat for Strategic Planning, Ministry of Health, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[{"name":"Cardiovascular Division &amp; Center for Cardiometabolic Implementation Science, Brigham &amp; Women's Hospital, Harvard Medical School, Boston, MA 02115, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4306-5317","authenticated-orcid":false,"given":"Pardeep S","family":"Jhund","sequence":"additional","affiliation":[{"name":"British Heart Foundation, University of Glasgow, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"issue":"1","key":"e_1_3_7_3_2","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1017\/cts.2024.492","article-title":"Trends in use of composite endpoints in clinical trials: a comparison between acute heart failure trials and COVID-19 trials","volume":"8","author":"Shi L","year":"2024","unstructured":"Shi L, Lindsell CJ, Liu D. Trends in use of composite endpoints in clinical trials: a comparison between acute heart failure trials and COVID-19 trials. J. Clin. Transl. Sci. 8(1), e55 (2024).","journal-title":"J. Clin. Transl. Sci."},{"issue":"23","key":"e_1_3_7_4_2","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.117.026229","article-title":"composite end points in clinical research: a time for reappraisal","volume":"135","author":"Armstrong PW","year":"2017","unstructured":"Armstrong PW, Westerhout CM. composite end points in clinical research: a time for reappraisal. Circulation 135(23), 2299\u20132307 (2017).","journal-title":"Circulation"},{"issue":"10","key":"e_1_3_7_5_2","doi-asserted-by":"crossref","first-page":"e240117","DOI":"10.57264\/cer-2024-0117","article-title":"Composite endpoints in health technology assessment: part 1 \u2013 an illustration of best modelling practice","volume":"14","author":"Briggs A","year":"2025","unstructured":"Briggs A, Angelis A, Chen J Composite endpoints in health technology assessment: part 1 \u2013 an illustration of best modelling practice. J. Comp. Eff. Res. 14(10), e240117 (2025).","journal-title":"J. Comp. Eff. Res."},{"issue":"12","key":"e_1_3_7_6_2","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon SD","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N. Engl. J. Med. 387(12), 1089\u20131098 (2022).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_7_7_2","unstructured":"National Institute for Health and Care Excellence. NICE health technology evaluations: the manual (2023). Available from: https:\/\/www.nice.org.uk\/process\/pmg36\/resources\/nice-health-technology-evaluations-the-manual-pdf-72286779244741 (Accessed: 14 November 2024)."},{"issue":"20","key":"e_1_3_7_8_2","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular\u2013kidney\u2013metabolic health: a Presidential Advisory from the American Heart Association","volume":"148","author":"Ndumele CE","year":"2023","unstructured":"Ndumele CE, Rangaswami J, Chow SL Cardiovascular\u2013kidney\u2013metabolic health: a Presidential Advisory from the American Heart Association. Circulation 148(20), 1606\u20131635 (2023).","journal-title":"Circulation"},{"key":"e_1_3_7_9_2","article-title":"Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction","author":"National Institute for Health and Care Excellence","year":"2023","unstructured":"National Institute for Health and Care Excellence. Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction. Final Draft Guidance, (2023). Available from: https:\/\/www.nice.org.uk\/guidance\/ta902\/documents\/final-appraisal-determination-document (Accessed: 14 November 2024).","journal-title":"Final Draft Guidance"},{"issue":"21","key":"e_1_3_7_10_2","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray JJV","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 381(21), 1995\u20132008 (2019).","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"e_1_3_7_11_2","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer M","year":"2020","unstructured":"Packer M, Anker SD, Butler J Cardiovascular and renal outcomes with empagliflozin in heart failure. N. Engl. J. Med. 383(15), 1413\u20131424 (2020).","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"e_1_3_7_12_2","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker SD","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G Empagliflozin in heart failure with a preserved ejection fraction. N. Engl. J. Med. 385(16), 1451\u20131461 (2021).","journal-title":"N. Engl. J. Med."},{"issue":"10354","key":"e_1_3_7_13_2","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan M","year":"2022","unstructured":"Vaduganathan M, Docherty KF, Claggett BL SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet 400(10354), 757\u2013767 (2022).","journal-title":"Lancet"},{"issue":"9","key":"e_1_3_7_14_2","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1038\/s41591-022-01971-4","article-title":"Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER","volume":"28","author":"Jhund PS","year":"2022","unstructured":"Jhund PS, Kondo T, Butt JH Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nat. Med. 28(9), 1956\u20131964 (2022).","journal-title":"Nat. Med."},{"issue":"22","key":"e_1_3_7_15_2","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1016\/j.jacc.2024.08.033","article-title":"Why have we not been able to demonstrate reduced mortality in patients with HFmrEF\/HFpEF?","volume":"84","author":"Kondo T","year":"2024","unstructured":"Kondo T, Henderson AD, Docherty KF Why have we not been able to demonstrate reduced mortality in patients with HFmrEF\/HFpEF? J. Am. Coll. Cardiol. 84(22), 2233\u20132240 (2024).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"8","key":"e_1_3_7_16_2","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1002\/ejhf.2940","article-title":"The cost-effectiveness of dapagliflozin in heart failure with preserved or mildly reduced ejection fraction: a European health-economic analysis of the DELIVER trial","volume":"25","author":"Booth D","year":"2023","unstructured":"Booth D, Davis JA, McEwan P The cost-effectiveness of dapagliflozin in heart failure with preserved or mildly reduced ejection fraction: a European health-economic analysis of the DELIVER trial. Eur. J. Heart Fail. 25(8), 1386\u20131395 (2023).","journal-title":"Eur. J. Heart Fail."},{"key":"e_1_3_7_17_2","unstructured":"Electronic medicines compendium. Forxiga 10 mg film-coated tablets SmPC (2024). Available from: https:\/\/www.medicines.org.uk\/emc\/product\/7607\/smpc (Accessed: 14 November 2024)."},{"key":"e_1_3_7_18_2","unstructured":"DAILYMED. FARXIGA- dapagliflozin tablet film coated (2024). Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/lookup.cfm?setid=40cc4f5d-bcf6-4016-9d1e-838bbc4bdddc (Accessed: 14 November 2024)."},{"issue":"9185","key":"e_1_3_7_19_2","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/S0140-6736(99)03190-6","article-title":"Are drugs within a class interchangeable?","volume":"354","author":"Furberg CD","year":"1999","unstructured":"Furberg CD, Herrington DM, Psaty BM. Are drugs within a class interchangeable? Lancet 354(9185), 1202\u20131204 (1999).","journal-title":"Lancet"},{"issue":"5","key":"e_1_3_7_20_2","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/S0735-1097(01)01161-5","article-title":"Are all angiotensin-converting enzyme inhibitors interchangeable?","volume":"37","author":"Furberg CD","year":"2001","unstructured":"Furberg CD, Pitt B. Are all angiotensin-converting enzyme inhibitors interchangeable? J. Am. Coll. Cardiol. 37(5), 1456\u20131460 (2001).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"e_1_3_7_21_2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0735-1097(02)01913-7","article-title":"Physicians' interpretation of \u201cclass effects\u201d: a need for thoughtful re-evaluation","volume":"40","author":"Kennedy HL","year":"2002","unstructured":"Kennedy HL, Rosenson RS. Physicians' interpretation of \u201cclass effects\u201d: a need for thoughtful re-evaluation. J. Am. Coll. Cardiol. 40(1), 19\u201326 (2002).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"14","key":"e_1_3_7_22_2","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1001\/jama.282.14.1371","article-title":"Users' Guides to the Medical Literature: XIX. Applying clinical trial results B. Guidelines for determining whether a drug is exerting (more than) a class effect","volume":"282","author":"McAlister FA","year":"1999","unstructured":"McAlister FA, Laupacis A, Wells GA, Sackett DL. Users' Guides to the Medical Literature: XIX. Applying clinical trial results B. Guidelines for determining whether a drug is exerting (more than) a class effect. JAMA 282(14), 1371\u20131377 (1999).","journal-title":"JAMA"},{"issue":"5","key":"e_1_3_7_23_2","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/eurheartj\/ehab798","article-title":"Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction","volume":"43","author":"Butler J","year":"2022","unstructured":"Butler J, Packer M, Filippatos G Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. Eur. Heart J. 43(5), 416\u2013426 (2022).","journal-title":"Eur. Heart J."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2025-0012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T10:51:12Z","timestamp":1758797472000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2025-0012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.57264\/cer-2025-0012"],"URL":"https:\/\/doi.org\/10.57264\/cer-2025-0012","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"type":"print","value":"2042-6305"},{"type":"electronic","value":"2042-6313"}],"subject":[],"published":{"date-parts":[[2025,10]]},"article-number":"e250012"}}